Vladimír Džavík
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vladimír Džavík has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
Christopher E. Buller
From the University of Tromsoe (T.K.S.), Tromsoe, Norway; Division of Cardiology (C.E.B., G.B.J.M.), Vancouver General Hospital, Vancouver, British Columbia, Canada; Columbia University Division of Cardiology (V.J., G.A.L.), Mount Sinai Medical Center, Miami Beach, Fla; Division of Cardiology (W.J.C.), Southlake Regional Health Center, Newmarket, Ontario, Canada; Department of Cardiovascular Medicine (J.M.R.), Royal Perth Hospital, Perth, Australia; Hospital Fernando Fonseca (B.T.), Lisbon,...
5 shared publications- Judith S. Hochman
New York University School of Medicine, New York, New York
4 shared publications Karen Mackie
Peter Munk Cardiac Centre, University Health Network, Interventional Cardiology Program, Division of Cardiology, Toronto, Ontario, Canada
4 shared publicationsAli S. Almasood
Peter Munk Cardiac Centre, University Health Network, Interventional Cardiology Program, Division of Cardiology, Toronto, Ontario, Canada
3 shared publicationsEric A. Cohen
Sunnybrook Health Sciences Centre, Toronto, Ontario
3 shared publications- Eric Horlick
Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
3 shared publications
Latest Publications
- 17 April 2012
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 81 (1)
Choice of stent and outcomes after treatment of drug-eluting stent restenosis in highly complex lesions
Objectives Our aim was to compare the outcomes of a same versus different drug‐eluting stent (DES) implantation strategy for the treatment of DES instent restenosis (ISR). Background The absence of clear data renders the treatment of DES ISR one of the most challenging situations in interventional cardiology. Methods We identified all cases of DES ISR treated with a second DES between January 2004 and January 2009. The lesions were divided into those treated with the same DES as the initial one that restenosed and those treated with a different DES. The main end‐point was repeat target lesion revascularization (TLR). Results We included 116 patients with a total of 132 lesions. The patient population was highly complex: 55.5% with diabetes, 56% with type‐C lesions, 15.9% with lesions previously stented with BMS and 18.2% with fluoroscopic evidence of stent fracture. A same and different stent strategy was conducted in 41 lesions (31%) and 91 lesions (69%), respectively. Overall TLR was 31.1% and occurred in 46.3% of patients treated with the same stent and 24.4% of those with a different stent (P = 0.012). Multivariable analysis found same stent strategy (OR 2.84, 95%CI 1.23–6.57;P = 0.014) and occurrence of stent fracture (OR 4.03, 95%CI 1.33–12.01;P = 0.012) to be the only independent predictors of TLR after a median follow‐up of 20.4 [12.1–30.2] months. Conclusions In highly complex lesions, DES implantation for DES ISR is linked to a high need of future revascularization. An association between implanting a DES type other than the original and lower rate of TLR is suggested.
- 17 April 2012
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 81 (1)
Choice of stent and outcomes after treatment of drug-eluting stent restenosis in highly complex lesions
Objectives Our aim was to compare the outcomes of a same versus different drug‐eluting stent (DES) implantation strategy for the treatment of DES instent restenosis (ISR). Background The absence of clear data renders the treatment of DES ISR one of the most challenging situations in interventional cardiology. Methods We identified all cases of DES ISR treated with a second DES between January 2004 and January 2009. The lesions were divided into those treated with the same DES as the initial one that restenosed and those treated with a different DES. The main end‐point was repeat target lesion revascularization (TLR). Results We included 116 patients with a total of 132 lesions. The patient population was highly complex: 55.5% with diabetes, 56% with type‐C lesions, 15.9% with lesions previously stented with BMS and 18.2% with fluoroscopic evidence of stent fracture. A same and different stent strategy was conducted in 41 lesions (31%) and 91 lesions (69%), respectively. Overall TLR was 31.1% and occurred in 46.3% of patients treated with the same stent and 24.4% of those with a different stent (P = 0.012). Multivariable analysis found same stent strategy (OR 2.84, 95%CI 1.23–6.57;P = 0.014) and occurrence of stent fracture (OR 4.03, 95%CI 1.33–12.01;P = 0.012) to be the only independent predictors of TLR after a median follow‐up of 20.4 [12.1–30.2] months. Conclusions In highly complex lesions, DES implantation for DES ISR is linked to a high need of future revascularization. An association between implanting a DES type other than the original and lower rate of TLR is suggested.
- Open Access
- 1 February 2012
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 5 (1) , 127-133
Radial Artery Patency After Transradial Catheterization
T he transradial approach to cardiac catheterization has many advantages over the transfemoral approach and is increasingly being used for both diagnostic coronary angiography and percutaneous coronary intervention (PCI). The technique is associated with fewer vascular access complications 1-3 and has been shown to reduce major bleeding when compared with the femoral approach. 4 Patients prefer the radial approach and score higher on quality-of-life questionnaires after transradial catheterization. 3,5 Radial access allows for earlier patient ambulation and same-day hospital discharge in PCI patients 4-6 and is associated with decreased cost. 5,7,8 Radial artery occlusion (RAO) is a complication of transradial catheterization that can lead to permanent occlusion of the radial artery. Estimated to occur in 1-10% of cases, 9-14 it has been described as the "Achilles' heel" of the transradial technique. 15 RAO is usually clinically silent because of the dual blood supply to the hand, and for this reason it is often overlooked. In fact, more than 50% of transradial operators do not routinely assess radial artery patency before hospital discharge. 16 However, the complication is not benign, as hand ischemia resulting from RAO has been reported. 17-19 Furthermore, once the artery is occluded, it cannot be used as an access site for future catheterization or as an arterial conduit for bypass surgery. RAO renders the ipsilateral ulnar artery unusable as well, because instrumenting and cannulating the ulnar would put the patient's hand at risk of ischemia. In this report, we review the pathophysiology, clinical presentation, and risk factors for RAO, discuss prevention and treatment options, and suggest directions for future research aimed at minimizing this complication.
- 1 February 2012
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 5 (1) , 127-133
Open AccessRadial Artery Patency After Transradial Catheterization
T he transradial approach to cardiac catheterization has many advantages over the transfemoral approach and is increasingly being used for both diagnostic coronary angiography and percutaneous coronary intervention (PCI). The technique is associated with fewer vascular access complications 1-3 and has been shown to reduce major bleeding when compared with the femoral approach. 4 Patients prefer the radial approach and score higher on quality-of-life questionnaires after transradial catheterization. 3,5 Radial access allows for earlier patient ambulation and same-day hospital discharge in PCI patients 4-6 and is associated with decreased cost. 5,7,8 Radial artery occlusion (RAO) is a complication of transradial catheterization that can lead to permanent occlusion of the radial artery. Estimated to occur in 1-10% of cases, 9-14 it has been described as the "Achilles' heel" of the transradial technique. 15 RAO is usually clinically silent because of the dual blood supply to the hand, and for this reason it is often overlooked. In fact, more than 50% of transradial operators do not routinely assess radial artery patency before hospital discharge. 16 However, the complication is not benign, as hand ischemia resulting from RAO has been reported. 17-19 Furthermore, once the artery is occluded, it cannot be used as an access site for future catheterization or as an arterial conduit for bypass surgery. RAO renders the ipsilateral ulnar artery unusable as well, because instrumenting and cannulating the ulnar would put the patient's hand at risk of ischemia. In this report, we review the pathophysiology, clinical presentation, and risk factors for RAO, discuss prevention and treatment options, and suggest directions for future research aimed at minimizing this complication.
- 1 July 2011
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 4 (4) , 440-447
Temporal Trends in Cardiogenic Shock Treatment and Outcomes Among Ontario Patients With Myocardial Infarction Between 1992 and 2008
Background—: Clinical trials have demonstrated that emergent revascularization improves survival of patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS). However, rates of uptake and impact on outcomes remain uncertain. Methods and Results—: We identified 9750 patients (3.1%) with CS among 311 183 AMI patients in the Ontario Myocardial Infarction Database between 1992 and 2008 (55.8% men; mean age, 73 years). CS incidence, mortality, revascularization, and transfers from nonrevascularization sites were studied over 3 periods: period 1, before the 1999 American College of Cardiology/American Heart Association AMI guidelines recommending urgent revascularization for patients P P P <0.001). Conclusions—: Publication of American College of Cardiology/American Heart Association guidelines was followed by increased revascularization and transfer rates, along with declining mortality rates among Ontario AMI patients with CS. These results highlight possibilities for further improvement, particularly among patients eligible for transfer from nonrevascularization sites.
- 1 July 2011
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 4 (4) , 440-447
Temporal Trends in Cardiogenic Shock Treatment and Outcomes Among Ontario Patients With Myocardial Infarction Between 1992 and 2008
Background—: Clinical trials have demonstrated that emergent revascularization improves survival of patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS). However, rates of uptake and impact on outcomes remain uncertain. Methods and Results—: We identified 9750 patients (3.1%) with CS among 311 183 AMI patients in the Ontario Myocardial Infarction Database between 1992 and 2008 (55.8% men; mean age, 73 years). CS incidence, mortality, revascularization, and transfers from nonrevascularization sites were studied over 3 periods: period 1, before the 1999 American College of Cardiology/American Heart Association AMI guidelines recommending urgent revascularization for patients P P P <0.001). Conclusions—: Publication of American College of Cardiology/American Heart Association guidelines was followed by increased revascularization and transfer rates, along with declining mortality rates among Ontario AMI patients with CS. These results highlight possibilities for further improvement, particularly among patients eligible for transfer from nonrevascularization sites.
- 12 May 2011
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 79 (4) , 559-565
Decreased risk of stent fracture-related restenosis between paclitaxel-eluting stents and sirolimus eluting stents: Results of long-term follow-up
- 12 May 2011
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 79 (4) , 559-565
Decreased risk of stent fracture-related restenosis between paclitaxel-eluting stents and sirolimus eluting stents: Results of long-term follow-up
- Open Access
- 1 January 2011
- Published by Hindawi Limited in Cardiology Research and Practice
- Vol. 2011, 1-5
Stent Fracture after Everolimus-Eluting Stent Implantation
Compared with bare-metal stents, drug-eluting stents (DES) have greatly reduced the risk of in-stent restenosis (ISR) by inhibiting neointimal growth. Nevertheless, DES are still prone to device failure, which may lead to cardiac events. Recently, stent fracture (SF) has emerged as a potential mechanism of DES failure that is associated with ISR. Stent fracture is strongly related to stent type, and prior reports suggest that deployment of sirolimus eluting stents (SES) may be associated with a higher risk of SF compared to other DES. Everolimus eluting stents (EESs) represent a new generation of DES with promising results. The occurrence of SF with EES has not been well established. The present paper describes two cases of EES fracture associated with ISR.
- 1 January 2011
- Published by Hindawi Limited in Cardiology Research and Practice
- Vol. 2011, 1-5
Open AccessStent Fracture after Everolimus-Eluting Stent Implantation
Compared with bare-metal stents, drug-eluting stents (DES) have greatly reduced the risk of in-stent restenosis (ISR) by inhibiting neointimal growth. Nevertheless, DES are still prone to device failure, which may lead to cardiac events. Recently, stent fracture (SF) has emerged as a potential mechanism of DES failure that is associated with ISR. Stent fracture is strongly related to stent type, and prior reports suggest that deployment of sirolimus eluting stents (SES) may be associated with a higher risk of SF compared to other DES. Everolimus eluting stents (EESs) represent a new generation of DES with promising results. The occurrence of SF with EES has not been well established. The present paper describes two cases of EES fracture associated with ISR.
- Open Access
- 7 December 2010
- Published by Wolters Kluwer Health in Circulation
- Vol. 122 (23) , 2411-2418
The sPLA2Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial
Background—: Secretory phospholipase A2(sPLA2) may play a role in myonecrosis after elective percutaneous coronary intervention (PCI). Inhibition of this enzyme may have a beneficial effect. The central hypothesis of this study was that treatment with varespladib, a small-molecule inhibitor of sPLA2would reduce postprocedural release of cardiac biomarkers after elective percutaneous coronary intervention.Methods and Results—: Between October 2007 and June 2009, 144 stable patients were randomized in a phase II trial to receive varespladib 500 mg PO BID or placebo 3 to 5 days before and for 5 days after elective percutaneous coronary intervention. The primary end point was elevation of troponin I or creatine kinase-MB above the upper limit of normal at 6 to 8 or 18 to 24 hours after percutaneous coronary intervention. Mean age was 63±10 and 64±10 years, with 38% and 42% with diabetes mellitus and 29% and 28% with prior myocardial infarction for the varespladib and placebo groups, respectively. The primary end point occurred in 75% of varespladib and 63% of placebo patients (P=0.14). Troponin I 3 times the upper limit of normal was observed in 57% and 50% (P=0.39) and creatine kinase-MB 2 times the upper limit of normal in 14% and 3% (P=0.018). Median (first and third quartiles) change in high-sensitivity C-reactive protein in these 2 groups was 0.65 mg/L (−0.18 and 1.48) and 0.70 mg/L (0.00 and 1.50) at 18 to 24 hours (P=0.81) and 0.20 mg/L (−0.70 and 1.40) and 0.60 mg/L (−0.12 and 1.72) at 3 to 5 days (P=0.23), whereas change in sPLA2activity at 3 to 5 days in a subset was −2.85 ng/ml (−3.40 and −1.85) and 0.25 ng/ml (−0.20 and 0.85) (P2by varespladib administered for 3 to 5 days before the procedure does not reduce periprocedural myonecrosis associated with elective percutaneous coronary intervention.Clinical Trial Registration—: URL:http://www.clinicaltrials.gov. Unique identifier: NCT00533039.
- 7 December 2010
- Published by Wolters Kluwer Health in Circulation
- Vol. 122 (23) , 2411-2418
Open AccessThe sPLA2Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial
Background—: Secretory phospholipase A2(sPLA2) may play a role in myonecrosis after elective percutaneous coronary intervention (PCI). Inhibition of this enzyme may have a beneficial effect. The central hypothesis of this study was that treatment with varespladib, a small-molecule inhibitor of sPLA2would reduce postprocedural release of cardiac biomarkers after elective percutaneous coronary intervention.Methods and Results—: Between October 2007 and June 2009, 144 stable patients were randomized in a phase II trial to receive varespladib 500 mg PO BID or placebo 3 to 5 days before and for 5 days after elective percutaneous coronary intervention. The primary end point was elevation of troponin I or creatine kinase-MB above the upper limit of normal at 6 to 8 or 18 to 24 hours after percutaneous coronary intervention. Mean age was 63±10 and 64±10 years, with 38% and 42% with diabetes mellitus and 29% and 28% with prior myocardial infarction for the varespladib and placebo groups, respectively. The primary end point occurred in 75% of varespladib and 63% of placebo patients (P=0.14). Troponin I 3 times the upper limit of normal was observed in 57% and 50% (P=0.39) and creatine kinase-MB 2 times the upper limit of normal in 14% and 3% (P=0.018). Median (first and third quartiles) change in high-sensitivity C-reactive protein in these 2 groups was 0.65 mg/L (−0.18 and 1.48) and 0.70 mg/L (0.00 and 1.50) at 18 to 24 hours (P=0.81) and 0.20 mg/L (−0.70 and 1.40) and 0.60 mg/L (−0.12 and 1.72) at 3 to 5 days (P=0.23), whereas change in sPLA2activity at 3 to 5 days in a subset was −2.85 ng/ml (−3.40 and −1.85) and 0.25 ng/ml (−0.20 and 0.85) (P2by varespladib administered for 3 to 5 days before the procedure does not reduce periprocedural myonecrosis associated with elective percutaneous coronary intervention.Clinical Trial Registration—: URL:http://www.clinicaltrials.gov. Unique identifier: NCT00533039.
- 1 December 2010
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 3 (6) , 549-555
Myocardial Perfusion Grade After Late Infarct Artery Recanalization Is Associated With Global and Regional Left Ventricular Function at One Year
Whether myocardial perfusion grade (MPG) following late recanalization of infarct-related arteries (IRAs) predicts left ventricular (LV) function recovery beyond the acute phase of myocardial infarction (MI) is unknown. The Total Occlusion Study of Canada-2 enrolled stable patients with a persistently occluded IRA beyond 24 hours and up to 28 days post-MI. We studied the relationship between the initial MPG and changes in LV function and volume as well as the change in MPG from immediate post-percutaneous coronary intervention (PCI) to 1 year in 139 PCI patients with thrombolysis in myocardial infarction grade 3 epicardial flow post-PCI and with paired values grouped into impaired or good MPG groups (MPG 0/1 or MPG 2/3). MPG 0/1 patients were more likely to have received thrombolytic therapy and to have a left anterior descending IRA. They had lower blood pressure and LV ejection fraction (LVEF) and a higher heart rate and systolic sphericity index at baseline. Changes in the MPG 0/1 and MPG 2/3 groups from baseline to 1 year were LVEF, 3.3±9.0% and 4.8±8.9% ( P =0.42); LV end-systolic volume index (LVESVI), −1.1±9.2 and −4.7±12.3 mL/m 2 ( P =0.25); LV end-diastolic volume index (LVEDVI), 0.08±19.1 and −2.4±22.2 mL/m 2 ( P =0.67); and SDs/chord for infarct zone wall motion index (WMI), 0.38±0.70 and 0.84±1.11 ( P =0.01). By covariate-adjusted analysis, post-PCI MPG 0/1 predicted lower WMI ( P P P <0.01) but not LVEDVI at 1 year. Of the MPG 0/1 patients, 60% were MPG 2 or 3 at 1 year. Preserved MPG is present in a high proportion of patients following late PCI of occluded IRAs post-MI. Poor MPG post-PCI frequently improves MPG over 1 year. MPG graded after IRA recanalization undertaken days to weeks post MI is associated with LV recovery, indicating that MPG determined in the subacute post-MI period remains a marker of viability. URL: http://www.clinicaltrials.gov . Unique identifier: NCT00025766.
- 1 December 2010
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 3 (6) , 549-555
Myocardial Perfusion Grade After Late Infarct Artery Recanalization Is Associated With Global and Regional Left Ventricular Function at One Year
Whether myocardial perfusion grade (MPG) following late recanalization of infarct-related arteries (IRAs) predicts left ventricular (LV) function recovery beyond the acute phase of myocardial infarction (MI) is unknown. The Total Occlusion Study of Canada-2 enrolled stable patients with a persistently occluded IRA beyond 24 hours and up to 28 days post-MI. We studied the relationship between the initial MPG and changes in LV function and volume as well as the change in MPG from immediate post-percutaneous coronary intervention (PCI) to 1 year in 139 PCI patients with thrombolysis in myocardial infarction grade 3 epicardial flow post-PCI and with paired values grouped into impaired or good MPG groups (MPG 0/1 or MPG 2/3). MPG 0/1 patients were more likely to have received thrombolytic therapy and to have a left anterior descending IRA. They had lower blood pressure and LV ejection fraction (LVEF) and a higher heart rate and systolic sphericity index at baseline. Changes in the MPG 0/1 and MPG 2/3 groups from baseline to 1 year were LVEF, 3.3±9.0% and 4.8±8.9% ( P =0.42); LV end-systolic volume index (LVESVI), −1.1±9.2 and −4.7±12.3 mL/m 2 ( P =0.25); LV end-diastolic volume index (LVEDVI), 0.08±19.1 and −2.4±22.2 mL/m 2 ( P =0.67); and SDs/chord for infarct zone wall motion index (WMI), 0.38±0.70 and 0.84±1.11 ( P =0.01). By covariate-adjusted analysis, post-PCI MPG 0/1 predicted lower WMI ( P P P <0.01) but not LVEDVI at 1 year. Of the MPG 0/1 patients, 60% were MPG 2 or 3 at 1 year. Preserved MPG is present in a high proportion of patients following late PCI of occluded IRAs post-MI. Poor MPG post-PCI frequently improves MPG over 1 year. MPG graded after IRA recanalization undertaken days to weeks post MI is associated with LV recovery, indicating that MPG determined in the subacute post-MI period remains a marker of viability. URL: http://www.clinicaltrials.gov . Unique identifier: NCT00025766.
- 17 December 2009
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 75 (7) , 1037-1044
Selective use of embolic protection devices during saphenous vein grafts interventions: A single‐center experience
Objectives: To report on outcomes with selective use of embolic protection devices (EPD) during percutaneous coronary intervention (PCI) to saphenous vein grafts (SVG). Background: PCI to SVG is associated with increased risk and the use of EPD is recommended in this setting. Methods: Angiographic and clinical outcomes were prospectively obtained from 534 consecutive patients who underwent PCI to SVG with or without EPD at a tertiary cardiac centre. Long‐term outcomes were obtained by linkage to a provincial registry. Results: EPD, deployed in 198 of 373 SVGs (53%) suitable for deployment of a distal EPD, were used more often in ectatic (33% vs. 19%, P = 0.003), ulcerated (17% vs. 9%, P = 0.03), thrombotic (26% vs. 10%, P < 0.0001) vein grafts, with longer degenerated segments (P = 0.002), and in lesions involving the body of the graft (85% vs. 66%, P < 0.0001), and less with lesions involving the graft ostium (29% vs. 44%, P = 0.003). Patients suitable for but not receiving EPD tended to be more likely to have a periprocedural myocardial infarction. During 3 years of follow‐up, 49% of the patients had a cardiovascular event. Cumulative mortality was 8.4%, 18.8% and 14.7% in patients unsuitable for distal EPD, suitable but without EPD, and with EPD (p = 0.11). Nonuse of EPD was an independent predictor of MACE at 3 years. (P = 0.02). Conclusions: Selective use of EPD is associated with low in‐hospital cardiovascular event rates. Long‐term outcomes are manifested by a high rate of events, especially in patients with SVG's suitable for but not receiving EPD. This suggests that routine use of distal EPD may be warranted in unselected patients with suitable SVG anatomy.
- 17 December 2009
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 75 (7) , 1037-1044
Selective use of embolic protection devices during saphenous vein grafts interventions: A single‐center experience
Objectives: To report on outcomes with selective use of embolic protection devices (EPD) during percutaneous coronary intervention (PCI) to saphenous vein grafts (SVG). Background: PCI to SVG is associated with increased risk and the use of EPD is recommended in this setting. Methods: Angiographic and clinical outcomes were prospectively obtained from 534 consecutive patients who underwent PCI to SVG with or without EPD at a tertiary cardiac centre. Long‐term outcomes were obtained by linkage to a provincial registry. Results: EPD, deployed in 198 of 373 SVGs (53%) suitable for deployment of a distal EPD, were used more often in ectatic (33% vs. 19%, P = 0.003), ulcerated (17% vs. 9%, P = 0.03), thrombotic (26% vs. 10%, P < 0.0001) vein grafts, with longer degenerated segments (P = 0.002), and in lesions involving the body of the graft (85% vs. 66%, P < 0.0001), and less with lesions involving the graft ostium (29% vs. 44%, P = 0.003). Patients suitable for but not receiving EPD tended to be more likely to have a periprocedural myocardial infarction. During 3 years of follow‐up, 49% of the patients had a cardiovascular event. Cumulative mortality was 8.4%, 18.8% and 14.7% in patients unsuitable for distal EPD, suitable but without EPD, and with EPD (p = 0.11). Nonuse of EPD was an independent predictor of MACE at 3 years. (P = 0.02). Conclusions: Selective use of EPD is associated with low in‐hospital cardiovascular event rates. Long‐term outcomes are manifested by a high rate of events, especially in patients with SVG's suitable for but not receiving EPD. This suggests that routine use of distal EPD may be warranted in unselected patients with suitable SVG anatomy.
- 16 December 2008
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 73 (6) , 771-779
Angiographic and clinical outcomes of drug‐eluting versus bare metal stent deployment in the Occluded Artery Trial
Background: The majority of patients randomized to percutaneous coronary intervention (PCI) in the Occluded Artery Trial (OAT) and its angiographic substudy, the Total Occlusion Study of Canada 2 (TOSCA‐2) were treated with bare metal stents (BMS). We aimed to determine if stenting of the target occlusion in OAT with drug‐eluting stents (DES) was associated with more favorable angiographic results and clinical outcome when compared with treatment with BMS.Methods: TOSCA‐2 DES was a prospective nonrandomized substudy that provided 1‐year angiographic comparison of late loss and reocclusion in 25 patients treated with DES and in 128 treated with BMS. In addition, all PCI‐assigned patients enrolled from the time when DES were first utilized were similarly categorized (DESn= 77, and BMSn= 386) and compared using the 3‐year cumulative OAT primary combined endpoint of death, myocardial infarction, or Class‐IV heart failure, as well as angina.Results: In‐segment late loss was 0.14 ± 0.45 mm for DES and 0.75 ± 0.86 mm for BMS (P< 0.001). Corresponding binary restenosis rates were 13.0% and 44.3% (P= 0.005). Occlusion at 1 year was observed in 4.0 and 12.1%, respectively (P= 0.23). The 3‐year cumulative primary event rate was 13.8% with DES and 12.5% with BMS (hazard ratio 1.08, 99% confidence intervals 0.44, 2.64;P= 0.83). Angina over time occurred less frequently in the DES group (P= 0.01).Conclusions: Although the reduction of late loss and trend to reduction in reocclusion with the use of DES for PCI of persistently occluded IRA 3–28 days post myocardial infarction did not translate into a signal for reduction in death, reinfarction, or Class IV heart failure, DES use was associated with less angina over time. Further follow‐up is warranted.
- 16 December 2008
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 73 (6) , 771-779
Angiographic and clinical outcomes of drug‐eluting versus bare metal stent deployment in the Occluded Artery Trial
Background: The majority of patients randomized to percutaneous coronary intervention (PCI) in the Occluded Artery Trial (OAT) and its angiographic substudy, the Total Occlusion Study of Canada 2 (TOSCA‐2) were treated with bare metal stents (BMS). We aimed to determine if stenting of the target occlusion in OAT with drug‐eluting stents (DES) was associated with more favorable angiographic results and clinical outcome when compared with treatment with BMS.Methods: TOSCA‐2 DES was a prospective nonrandomized substudy that provided 1‐year angiographic comparison of late loss and reocclusion in 25 patients treated with DES and in 128 treated with BMS. In addition, all PCI‐assigned patients enrolled from the time when DES were first utilized were similarly categorized (DESn= 77, and BMSn= 386) and compared using the 3‐year cumulative OAT primary combined endpoint of death, myocardial infarction, or Class‐IV heart failure, as well as angina.Results: In‐segment late loss was 0.14 ± 0.45 mm for DES and 0.75 ± 0.86 mm for BMS (P< 0.001). Corresponding binary restenosis rates were 13.0% and 44.3% (P= 0.005). Occlusion at 1 year was observed in 4.0 and 12.1%, respectively (P= 0.23). The 3‐year cumulative primary event rate was 13.8% with DES and 12.5% with BMS (hazard ratio 1.08, 99% confidence intervals 0.44, 2.64;P= 0.83). Angina over time occurred less frequently in the DES group (P= 0.01).Conclusions: Although the reduction of late loss and trend to reduction in reocclusion with the use of DES for PCI of persistently occluded IRA 3–28 days post myocardial infarction did not translate into a signal for reduction in death, reinfarction, or Class IV heart failure, DES use was associated with less angina over time. Further follow‐up is warranted.
- 1 November 2008
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 24 (11) , e82-e85
First Canadian experience with high-risk percutaneous coronary intervention with assistance of a percutaneously deployed left ventricular assist device
- 1 November 2008
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 24 (11) , e82-e85
First Canadian experience with high-risk percutaneous coronary intervention with assistance of a percutaneously deployed left ventricular assist device